SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (4171)3/24/2016 8:43:14 PM
From: jaybe   of 4474
 
For EGFR Exon 20 its "activity" naive, but afatinib, osimertinib, and EGF816 claim activity. But your point is well taken, since the majority of EGFR patients would have already tried erlotinib or gefitinib, if only for lack of any approved alternative, the majority could be 2L.

For Her2 Exon 20 its pan-HER naive, such as afatinib, neratinib, or dacomitinib. Since no TKIs are approved for these patients I think majority will be 1L.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News